Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Cancer and Metastasis Reviews
Erschienen in: Cancer and Metastasis Reviews 2/2008

01.06.2008

The role of serine/threonine protein phosphatase type 5 (PP5) in the regulation of stress-induced signaling networks and cancer

verfasst von: Teresa Golden, Mark Swingle, Richard E. Honkanen

Erschienen in: Cancer and Metastasis Reviews | Ausgabe 2/2008

Einloggen, um Zugang zu erhalten

Abstract

Although the aberrant actions of protein kinases have long been known to contribute to tumor promotion and carcinogenesis, roles for protein phosphatases in the development of human cancer have only emerged in the last decade. In this review, we discuss the data obtained from studies examining the biological and pathological roles of a serine/threonine protein phosphatase, PP5, which suggest that PP5 is a potentially important regulator of both hormone- and stress-induced signaling networks that enable a cell to respond appropriately to genomic stress.
Literatur
1.
Roberts, P. J., & Der, C. J. (2007). Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer. Oncogene, 26, 3291–3310.PubMedCrossRef
2.
Milano, A., De Rosa, V., Iaffaioli, R. V., & Caponigro, F. (2007). Downstream intracellular effectors of epidermal growth factor receptor as targets for anticancer therapy. Expert Opinion on Therapeutic Targets, 11, 771–782.PubMedCrossRef
3.
Schmitt, E., Paquet, C., Beauchemin, M., & Bertrand, R. (2007). DNA-damage response network at the crossroads of cell-cycle checkpoints, cellular senescence and apoptosis. Journal of Zhejiang University Science B, 8(6), 377–397.PubMedCrossRef
4.
Shenolikar, S., & Nairn, A. C. (1991). Protein phosphatases: Recent progress. Advances in Second Messenger and Phosphoprotein Research, 23, 1–119.PubMed
5.
Klumpp, S., & Krieglstein, J. (2002). Serine/threonine protein phosphatases in apoptosis. Current Opinion in Pharmacology, 2(4), 458–462.PubMedCrossRef
6.
Cohen, P. T. (2002). Protein phosphatase 1—targeted in many directions. Journal of Cell Science, 115(Pt 2), 241–256.PubMed
7.
Cohen, P. (1989). The structure and regulation of protein phosphatases. Annual Review of Biochemistry, 58, 453–508.PubMedCrossRef
8.
Cohen, P. T. (1997). Novel protein serine/threonine phosphatases: Variety is the spice of life. Trends in Biochemical Sciences, 22(7), 245–251.PubMedCrossRef
9.
Cohen, P. T. W., Brewis, N. D., Hughes, V., & Mann, D. J. (1990). Serine/threonine protein phosphatases: An expanding family. FEBS Letters, 268, 355–358.PubMedCrossRef
10.
Cohen, P. T. W. (1991). Cloning of protein–serine/threonine phosphatases. Methods in Enzymology, 201, 398–408.PubMedCrossRef
11.
Arndt, K. T., Styles, C. A., & Fink, G. R. (1989). A suppressor of HIS4 transcriptional defect encodes a protein with homology to the catalytic subunit of protein phosphatases. Cell, 56, 527–537.PubMedCrossRef
12.
Zhuang, Z., Dean, N. M., & Honkanen, R. E. (1998). Serine/threonine protein phosphatase type 5 acts upstream of p53 to regulate the induction of p21WAF1/Cip1 and mediate growth arrest. Journal of Biological Chemistry, 273(20), 12250–12258.CrossRef
13.
Silverstein, A. M., Galigniana, M. D., Chen, M. S., Owens-Grillo, J. K., Chinkers, M., & Pratt, W. B. (1997). Protein phosphatase 5 is a major component of glucocorticoid receptor.hsp90 complexes with properties of an FK506-binding immunophilin. Journal of Biological Chemistry, 272(26), 16224–16230.PubMedCrossRef
14.
Skinner, J., Sinclair, C., Romeo, C., Armstrong, D., Charbonneau, H., & Rossie, S. (1997). Purification of a fatty acid-stimulated protein-serine/threonine phosphatase from bovine brain and its identification as a homolog of protein phosphatase 5. Journal of Biological Chemistry, 272, 22464–22471.PubMedCrossRef
15.
Huang, X., Cheng, A., & Honkanen, R. E. (1997). Genomic organization of the human PP4 gene encoding a serine/threonine protein phosphatase (PP4) suggest a common ancestry with PP2A. Genomics, 44, 336–343.PubMedCrossRef
16.
Bastians, H., & Ponstingl, H. (1996). The novel human protein serine/threonine phosphatase 6 is a functional homologue of budding yeast Sit4p and fission yeast ppe1, which are involved in cell cycle regulation. Journal of Cell Science, 109(Pt 12), 2865–2874.PubMed
17.
Huang, X., & Honkanen, R. E. (1998). Molecular cloning, expression and characterization of a novel human serine/threonine protein phosphatase, PP7, that is homologous to Drosophila retinal degeneration C gene product (rdgC). Journal of Biological Chemistry, 273(3), 1462–1468.PubMedCrossRef
18.
Swingle, M. R., Honkanen, R. E., & Ciszak, E. M. (2004). Structural basis for the catalytic activity of human serine/threonine protein phosphatase-5. Journal of Biological Chemistry, 279(32), 33992–33999.PubMedCrossRef
19.
Yang, J., Roe, S. M., Cliff, M. J., Williams, M. A., Ladbury, J. E., Cohen, P. T. W., et al. (2005). Molecular basis for TPR domain-mediated regulation of protein phosphatase 5. The EMBO Journal, 24, 1–10.PubMedCrossRef
20.
Honkanen, R. E., Zwiller, J., Daily, S. L., Khatra, B. S., Dukelow, M., & Boynton, A. L. (1991). Identification, purification, and characterization of a novel serine/threonine protein phosphatase from bovine brain. Journal of Biological Chemistry, 266(10), 6614–6619.PubMed
21.
Becker, W., Kentrup, H., Klumpp, S., Schultz, J. E., & Joost, H. G. (1994). Molecular cloning of a protein serine threonine phosphatase containing a putative regulatory tetratricopeptide repeat domain. Journal of Biological Chemistry, 269, 22586–22592.PubMed
22.
Chen, M. X., McPartlin, A. E., Brown, L., Chen, Y. H., Barker, H. M., & Cohen, P. T. W. (1994). A novel human serine/threonine phosphatase, which possesses four tetratricopeptide repeat motifs and localizes to the nucleus. The EMBO Journal, 13(18), 4278–4290.PubMed
23.
Chinkers, M. (1994). Targeting of a distinctive protein–serine phosphatase to the protein kinase-like domain of the atrial natriuretic peptide receptor. Proceedings of the National Academy of Sciences of the United States of America, 91, 11075–11079.PubMedCrossRef
24.
Xu, X., Lagercrantz, J., Zickert, P., Bajalica-Lagercrantz, S., & Zetterberg, A. (1996). Chromosomal localization and 5” sequence of the human protein serine/threonine phosphatase 5 gene. Biochemical and Biophysical Research Communications, 218, 514–517.PubMedCrossRef
25.
Chen, M. S., Silverstein, A. M., Pratt, W. B., & Chinkers, M. (1996). The tetratricopeptide repeat domain of protein phosphatase 5 mediates binding to glucocorticoid receptor heterocomplexes and acts as a dominant negative mutant. Journal of Biological Chemistry, 271, 32315–32320.PubMedCrossRef
26.
Davies, T. H., Ning, Y. M., & Sanchez, E. R. (2005). Differential control of glucocorticoid receptor hormone-binding function by tetratricopeptide repeat (TPR) proteins and the immunosuppressive ligand FK506. Biochemistry, 44, 2030–2038.PubMedCrossRef
27.
Ollendorff, V., & Donoghue, D. J. (1997). The serine/threonine phosphatase PP5 interacts with CDC16 and CDC27, two tetratricopeptide repeat-containing subunits of the anaphase-promoting complex. Journal of Biological Chemistry, 272(51), 32011–32018.PubMedCrossRef
28.
Zhao, S., & Sancar, A. (1997). Human blue-light photoreceptor hCRY2 specifically interacts with protein serine/threonine phosphatase 5 and modulates its activity. Photochemistry and Photobiology, 66, 727–731.PubMedCrossRef
29.
Shao, J., Hartson, S. D., & Matts, R. L. (2002). Evidence that protein phosphatase 5 functions to negatively modulate the maturation of the Hsp90-dependent heme-regulated eIF2alpha kinase. Biochemistry, 41, 6770–6779.PubMedCrossRef
30.
Morita, K., Saitoh, M., Tobiume, K., Matsuura, H., Enomoto, S., Nishitoh, H., et al. (2001). Negative feedback regulation of ASK1 by protein phosphatase 5 (PP5) in response to oxidative stress. The EMBO Journal, 20, 6028–6036.PubMedCrossRef
31.
Wechsler, T., Chen, B. P., Harper, R., Morotomi-Yano, K., Huang, B. C., Meek, K., et al. (2004). DNA-PKcs function regulated specifically by protein phosphatase 5. Proceedings of the National Academy of Sciences of the United States of America, 101, 1247–1252.PubMedCrossRef
32.
Ali, A., Zhang, J., Bao, S., Liu, I., Otterness, D., Dean, N. M., et al. (2004). Requirement of protein phosphatase 5 in DNA-damage-induced ATM activation. Genes and Development, 18, 249–254.PubMedCrossRef
33.
Zhang, J., Bao, S., Furumai, R., Kucera, K. S., Ali, A., Dean, N. M. et al. (2005). Protein phosphatase 5 is required for ATR-mediated checkpoint activation. Molecular and Cellular Biology, 25(22), 9910–9919.PubMedCrossRef
34.
Lubert, E. J., Hong, Y., & Sarge, K. D. (2001). Interaction between protein phosphatase 5 and the A subunit of protein phosphatase 2A: Evidence for a heterotrimeric form of protein phosphatase 5. Journal of Biological Chemistry, 276(42), 38582–38587.PubMedCrossRef
35.
Yamaguchi, Y., Katoh, H., Mori, K., & Negishi, M. (2002). Galpha(12) and Galpha(13) interact with Ser/Thr protein phosphatase type 5 and stimulate its phosphatase activity. Current Biology, 12, 1353.PubMedCrossRef
36.
Gentile, S., Darden, T., Erxleben, C., Romeo, C., Russo, A., Martin, N., et al. (2006). Rac GTPase signaling through the PP5 protein phosphatase. Proceedings of the National Academy of Sciences of the United States of America, 103, 5202–5206.PubMedCrossRef
37.
von Kriegsheim, A., Pitt, A., Grindlay, G. J., Kolch, W., & Dhillon, A. S. (2006). Regulation of the Raf-MEK- ERK pathway by protein phosphatase 5. Nature Cell Biology, 8(9), 1011–1016.CrossRef
38.
Richter, K., & Buchner, J. (2001). Hsp90: Chaperoning signal transduction. Journal of Cellular Physiology, 188(3), 281–290.PubMedCrossRef
39.
Pratt, W. B., & Toft, D. O. (1997). Steroid receptor interactions with heat shock protein and immunophilin chaperones. Endocrine Reviews, 18, 306–360.PubMedCrossRef
40.
Frydman, J., & Höhfeld, J. (1997). Chaperones get in touch: The Hip–Hop connection. Trends in Biochemical Sciences, 22, 87–92.PubMedCrossRef
41.
Zuo, Z., Urban, G., Scammell, J. G., Dean, N. M., McLean, T. K., Aragon, I. V., et al. (1999). Ser/thr protein phosphatase type 5 (PP5) is a negative regulator of glucocorticoid receptor-mediated growth arrest. Biochemistry, 38(28), 8849–8857.PubMedCrossRef
42.
Dean, D. A., Urban, G., Aragon, I. V., Swingle, M., Miller, B., Rusconi, S., et al. (2001). Serine/threonine phosphatase 5 (PP5) participates in the regulation of glucocorticoid receptor nucleocytoplasmic shuttling. BMC Cell Biology, 2(6), 1471–2121.
43.
Riggs, D. L., Roberts, P. J., Chirillo, S. C., Cheung-Flynn, J., Prapapanich, V., Ratajczak, T., et al. (2003). The Hsp90-binding peptidylprolyl isomerase FKBP52 potentiates glucocorticoid signaling in vivo. The EMBO Journal, 22, 1158–1167.PubMedCrossRef
44.
Denny, W. B., Valentine, D. L., Reynolds, P. D., Smith, D. F., & Scammell, J. G. (2000). Squirrel monkey immunophilin FKBP51 is a potent inhibitor of glucocorticoid receptor binding. Endocrinology, 141, 4107–4113.PubMedCrossRef
45.
Davies, T. H., Ning, Y. M., & Sanchez, E. R. (2002). A new first step in activation of steroid receptors: Hormone-induced switching of FKBP51 and FKBP52 immunophilins. Journal of Biological Chemistry, 277, 4597–4600.PubMedCrossRef
46.
Wang, Z., Chen, W., Kono, E., Dang, T., & Garabedian, M. J. (2007). Modulation of glucocorticoid receptor phosphorylation and transcriptional activity by C-terminal-associated protein phosphatase. Molecular Endocrinology, 21, 625–634.PubMedCrossRef
47.
Conde, R., Xavier, J., McLoughlin, C., Chinkers, M., & Ovsenek, N. (2005). Protein phosphatase 5 is a negative modulator of heat shock factor 1. Journal of Biological Chemistry, 280, 28989–28996.PubMedCrossRef
48.
Sumanasekera, W. K., Tien, E. S., Davis, J. W., II, Turpey, R., Perdew, G. H., & Vanden Heuvel, J. P. (2003). Heat shock protein-90 (Hsp90) acts as a repressor of peroxisome proliferator-activated receptor alpha (PPARalpha) and PPARbeta activity. Biochemistry, 42(36), 10726–10735.PubMedCrossRef
49.
Meyer, B. K., Petrulis, J. R., & Perdew, J. H. (2000). Aryl hydrocarbon (Ah) receptor levels are selectively modulated by hsp90-associated immunophilin homolog XAP2. Cell Stress Chaperones, 5(3), 243–254.PubMedCrossRef
50.
Zuo, Z., Dean, N. M., & Honkanen, R. E. (1998). Serine/threonine protein phosphatase type 5 acts upstream of p53 to regulate the induction of p21WAF1/Cip1 and mediate growth arrest. Journal of Biological Chemistry, 273, 12250–12258.PubMedCrossRef
51.
Urban, G., Golden, T., Aragon, I. V., Cowsert, L., Cooper, S. R., Dean, N. M., et al. (2003). Identification of a functional link for the p53-tumor suppressor protein in dexamethasone induced growth suppression. Journal of Biological Chemistry, 278(11), 9747–9753.PubMedCrossRef
52.
53.
Zhang, Y., & Xiong, Y. (2001). A p53 Amino-terminal nuclear export signal inhibited by DNA damage-induced phosphorylation. Science, 292, 1910–1915.PubMedCrossRef
54.
Bean, L. J., & Stark, G. R. (2001). Phosphorylation of serines 15 and 37 is necessary for efficient accumulation of p53 following irradiation with UV. Oncogene, 20, 1076–1084.PubMedCrossRef
55.
Storey, N. M., O’Bryan, J. P., & Armstrong, D. L. (2002). Rac and Rho mediate opposing hormonal regulation of the ether-a-go-go-related potassium channel. Current Biology, 12, 27–33.PubMedCrossRef
56.
Dougherty, M., Müller, J., Ritt, D., Zhou, M., Zhou, X., Copeland, T., et al. (2005). Regulation of Raf-1 by direct feedback phosphorylation. Molecular Cell, 17, 215–224.PubMedCrossRef
57.
Urban, G., Golden, T., Aragon, I. V., Scammell, J. G., Dean, N. M., & Honkanen, R. E. (2001). Identification of an Estrogen-inducible Phosphatase (PP5) that converts MCF-7 Human Breast Carcinoma Cells into an Estrogen-Independent phenotype when expressed constitutively. Journal of Biological Chemistry, 276(29), 27638–27646.PubMedCrossRef
58.
Ikeda, k., Ogawa, S., Tsukui, T., Horie-Inoue, K., Ouchi, Y., Kato, S., et al. (2004). Protein phosphatase 5 is a negative regulator of estrogen receptor-mediated transcription. Molecular Endocrinology, 18, 1131–1143.PubMedCrossRef
59.
Golden, T., Aragon, I. V., Zhou, G., Cooper, S. R., Dean, N. M., & Honkanen, R. E. (2004). Constitutive over expression of serine/threonine protein phosphatase 5 (PP5) augments estrogen-dependent tumor growth in mice. Cancer Letters, 215, 95–100.PubMedCrossRef
60.
Zhou, G., Golden, T., Aragon, I. V., & Honkanen, R. E. (2004). Ser/thr protein phosphatase 5 (PP5) inactivates hypoxia-induced activation of an ASK-1/MKK-4/JNK-signaling cascade. Journal of Biological Chemistry, 279, 46595–46605.PubMedCrossRef
61.
Nagai, H., Noguchi, T., Takeda, K., & Ichijo, H. (2007). Pathophysiological roles of ASK1-MAP kinase signaling pathways. Biochemistry and Molecular Biology, 40, 1–6.PubMed
62.
Matsuzawa, A., Nishitoh, H., Tobiume, K., Takeda, K., & Ichijo, H. (2002). Physiological roles of ASK1-mediated signal transduction in oxidative stress- and endoplasmic reticulum stress-induced apoptosis: Advanced findings from ASK1 knockout mice. Antioxidants and Redox Signalling, 4, 415–425.CrossRef
63.
Huang, S., Shu, L., Easton, J., Harwood, F. C., Germain, G. S., Ichijo, H., et al. (2004). Inhibition of mammalian target of rapamycin activates apoptosis signal-regulating kinase 1 signaling by suppressing protein phosphatase 5 activity. Journal of Biological Chemistry, 279, 36490–36496.PubMedCrossRef
64.
DiBiase, S. J., Zeng, Z.-C., Chen, R., Hyslop, T., Curran, W. J., Jr., & Iliakis, G. (2000). DNA-dependent protein kinase stimulates an independently active, nonhomologous, end-joining apparatus. Canadian Research, 60, 1245–1253.
65.
Abraham, R. T. (2001). Cell cycle checkpoint signaling through the ATM and ATR kinases. Genes and Development, 15, 2177–2196.PubMedCrossRef
66.
Yong, W., Bao, S., Chen, H., Dapei, L., Sanchez, E. R., & Shou, W. (2007). Mice lacking protein phosphatase5 are defective in ataxia telangiectasia mutated (ATM)-mediated cell cycle arrest. Journal of Biological Chemistry, 282, 14690–14694.PubMedCrossRef
67.
Jeong, J.-Y., Johns, J., Sinclair, C., Park, J.-M., & Rossie, S. (2003). Characterization of Saccharomyces cerevisiae protein Ser/Thr phosphatase T1 and comparison to its mammalian homolog PP5. BMC Cell Biology, 4, 3.PubMedCrossRef
68.
Shirato, H., Shima, H., Nakagama, H., Fukuda, H., Watanabe, Y., Ogawa, K., et al. (2000). Expression in hepatomas and chromosomal localization of rat protein phosphatase 5 gene. International Journal of Oncology, 17, 909–912.PubMed
69.
Ghobrial, I. M., McCormick, D. J., Kaufmann, S. H., Leontovich, A. A., Loegering, D. A., Dai, N. T. et al. (2005). Proteomic analysis of mantle-cell lymphoma by protein microarray. Blood, 105, 3722–3730.PubMedCrossRef
70.
Atiye, J., Wolf, M., Kaur, S., Monni, O., Böhling, T., Kivioja, A. et al. (2005). Gene amplifications in osteosarcoma-CGH microarray analysis. Genes Chromosomes Cancer, 42(2), 158–163.PubMedCrossRef
71.
72.
Lad, C., Williams, N. H., & Wolfenden, R. (2003). The rate of hydrolysis of phosphomonoester dianions and the exceptional catalytic proficiencies of protein and inositol phosphatases. Proceedings of the National Academy of Sciences of the United States of America, 100, 5607–5610.PubMedCrossRef
73.
Maynes, J. T., Bateman, K. S., Cherney, M. M., Das, A. K., Luu, H. A., Holmes, C. F., & James, M. N. (2001). Crystal structure of the tumor-promoter okadaic acid bound to protein phosphatase-1. Journal of Biological Chemistry, 276, 44078–44082.PubMedCrossRef
74.
Griffith, J. P., Kim, J. L., Kim, E. E., Sintchak, M. D., Thomson, J. A., Fitzgibbon, M. J., et al. (1995). X-ray structure of calcineurin inhibited by the immunophilin-immunosuppressant FKBP12-FK506 complex. Cell, 82, 507–522.PubMedCrossRef
75.
Xing, Y., Xu, Y., Chen, Y., Jeffrey, P. D., Chao, Y., Lin, Z., Li, Z., Strack, S., Stock, J. B., & Shi, Y. (2006). Structure of protein phosphatase 2A core enzyme bound to tumor-inducing toxins. Cell, 127, 341–353.PubMedCrossRef
Metadaten
Titel
The role of serine/threonine protein phosphatase type 5 (PP5) in the regulation of stress-induced signaling networks and cancer
verfasst von
Teresa Golden
Mark Swingle
Richard E. Honkanen
Publikationsdatum
01.06.2008
Verlag
Springer US
Erschienen in
Cancer and Metastasis Reviews / Ausgabe 2/2008
Print ISSN: 0167-7659
Elektronische ISSN: 1573-7233
DOI
https://doi.org/10.1007/s10555-008-9125-z

Weitere Artikel der Ausgabe 2/2008

Cancer and Metastasis Reviews 2/2008 Zur Ausgabe

OriginalPaper

Dual-specificity MAP kinase phosphatases (MKPs) and cancer

OriginalPaper

Protein phosphatase 2A (PP2A), a drugable tumor suppressor in Ph1(+) leukemias

NON-THEMATIC REVIEW

Demethylation of (Cytosine-5-C-methyl) DNA and regulation of transcription in the epigenetic pathways of cancer development

NON-THEMATIC REVIEW

Targeted therapy for oesophageal cancer: an overview

Acknowledgments

Biography - Stephen M. Keyse

OriginalPaper

PRL PTPs: mediators and markers of cancer progression

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

23.04.2024 Medikamente in Schwangerschaft und Stillzeit Nachrichten

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise